Earnings Ahead

GKOS - Glaukos

69.52 0.73 1.06

Glaukos

Glaukos

About

Profile

We are an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. We have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditio


Headquarters

San Clemente, California, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

GKOS



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Glaukos Non-GAAP EPS of -$0.63 misses by $0.08, revenue of $82.37M beats by $3.84M
  • Glaukos Q4 2023 Earnings Preview
  • Glaukos says 2023 revenue to be in excess of $313M
  • Sight Sciences slips despite Medicare decision on glaucoma procedure (update)
  • Sight Sciences climbs after update on Medicare coverage for glaucoma procedure
  • JP Morgan raises Glaukos to buy; cites potential of iDose, iStent
  • BTIG makes top medtech stock picks for 2024, sees sector stabilizing
  • Glaukos stock jumps 15% on FDA approval of glaucoma drug
  • Truist starts Glaukos at buy, cites glaucoma market opportunity
  • Wells Fargo upgrades Glaukos to overweight, cites positive catalysts
  • Glaukos Non-GAAP EPS of -$0.50 beats by $0.05, revenue of $78M beats by $2.73M
  • Glaukos Q3 2023 Earnings Preview
  • Sight Sciences slumps amid risk for Medicare coverage for glaucoma procedure
  • Despite a slower Q2, Needham sees medtech market growing 7% in 2023
  • Glaukos Non-GAAP EPS of -$0.55 beats by $0.01, revenue of $80.4M beats by $5.74M
  • Glaukos Q2 2023 Earnings Preview
  • Glaukos enters marketing agreement with Radius XR
  • Sight Sciences cut to Neutral at Citi on reimbursement uncertainty
  • Glaukos said to have won regional Medicare coverage for glaucoma devices
  • Glaukos upgraded to overweight by Piper Sandler ahead of product launches
PEERS

Earnings History

Date EPS / Forecast Revenue / Forecast
February 22, 2022 -0.31 / -0.3724 73.24M / 67.27M Beat!
November 4, 2021 -0.21 / -0.2433 74.71M / 72.73M Beat!
August 5, 2021 -0.11 / -0.2461 78.09M / 71.32M Beat!
May 5, 2021 -0.21 / -0.3062 67.97M / 65.01M Beat!
February 25, 2021 -0.02 / -0.2917 73.23M / 68.31M Beat!
November 5, 2020 -0.09 / -0.4881 64.8M / 53.74M Beat!
August 6, 2020 -0.61 / -0.76 31.56M / 20.39M Beat!
May 7, 2020 -0.44 / -0.38 55.34M / 57.89M
February 27, 2020 -0.06 / -0.17 65.85M / 62.98M Beat!
November 6, 2019 -0.37 / -0.16 58.51M / 56.96M Beat!
August 7, 2019 -0.17 / -0.08 58.6M / 56.25M Beat!
May 8, 2019 -0.04 / -0.11 54.03M / 50.2M Beat!
February 27, 2019 0.04 / -0.13 54.08M / 49.6M Beat!
November 7, 2018 -0.19 / -0.14 43.91M / 41.65M Beat!
Date Price Open High Low Vol Change ER
Oct 9, 2023 71.71 71.24
72.72
71.14
226K -0.39%
Oct 6, 2023 71.99 69.61
72.82
69.56
451K 2.84%
Oct 5, 2023 70 69.24
70.95
68.11
421K 1.08%
Oct 4, 2023 69.25 71.38
71.41
68.7
443K -2.94%
Oct 3, 2023 71.35 70.81
71.79
69.99
730K 0.35%
 
Oct 2, 2023 71.1 74.8
74.8
70.09
772K -5.51%
Sep 29, 2023 75.25 76.26
76.26
74.2
783K -1.25%
Sep 28, 2023 76.2 78.99
79.69
76.11
513K -2.78%
Sep 27, 2023 78.38 75.85
78.84
75.85
644K 3.87%
Sep 26, 2023 75.46 75.98
77.45
75.4
480K -1.19%
Sep 25, 2023 76.37 75.05
76.64
74.64
303K 1.45%
Sep 22, 2023 75.28 75.57
76.45
75.06
486K 0.04%
Sep 21, 2023 75.25 75.25
75.75
74.86
581K -0.69%
Sep 20, 2023 75.77 77.09
78.07
75.71
645K -1.04%
Sep 19, 2023 76.57 75.79
77.23
75.42
615K 1.38%
Sep 18, 2023 75.53 74.95
76.35
74.78
199K 0.55%
Sep 15, 2023 75.12 75.27
75.27
73.96
793K -0.42%
Sep 14, 2023 75.44 76.38
76.86
74.45
236K -0.89%
Sep 13, 2023 76.12 76.45
76.65
75.28
227K -0.9%
Sep 12, 2023 76.81 76.22
78.95
76.22
503K 1.11%
Sep 11, 2023 75.97 75.16
76.11
74.42
279K 2.14%
Sep 8, 2023 74.38 75.55
76.02
73.78
266K -1.35%
Sep 7, 2023 75.4 76.75
77.82
74.8
409K -1.76%
Sep 6, 2023 76.75 74.11
77.24
73.8
492K 4.31%
Sep 5, 2023 73.58 74.06
74.32
71.61
465K -1.75%
Sep 1, 2023 74.89 75.36
76.11
74.88
207K -0.33%
Aug 31, 2023 75.14 75.82
75.9
74.55
204K -0.75%
Aug 30, 2023 75.71 75.6
76.92
75.45
253K 0.13%
Aug 29, 2023 75.61 73.82
76.24
73.82
353K 2.15%
Aug 28, 2023 74.02 74.44
74.82
73.53
271K 0.19%
Aug 25, 2023 73.88 74
74.38
72.68
180K 0.65%
Aug 24, 2023 73.4 74.97
74.97
72.9
330K -2.12%
Aug 23, 2023 74.99 75
75.23
74.01
223K 0.73%
Aug 22, 2023 74.45 73.21
74.63
72.83
274K 2.08%
Aug 21, 2023 72.93 72.06
73.35
71.83
412K 1.57%
Aug 18, 2023 71.8 71.52
72.86
71.43
532K -0.43%
Aug 17, 2023 72.11 73.88
74.07
72.06
451K -2.79%
Aug 16, 2023 74.18 74.95
76.16
73.78
261K -1.13%
Aug 15, 2023 75.03 73.68
75.32
72.55
584K 1.65%
Aug 14, 2023 73.81 74
74.52
73.38
418K -0.78%
Aug 11, 2023 74.39 73.15
74.52
72.98
193K 0.74%
Aug 10, 2023 73.84 72.72
74.26
72.48
268K 1.88%
Aug 9, 2023 72.48 74.59
75.22
71.6
399K -3.08%
Aug 8, 2023 74.78 74.79
75.16
73.71
332K -0.53%
Aug 7, 2023 75.18 74.55
75.81
74.05
436K 1.02%
Aug 4, 2023 74.42 74.18
75.6
72.59
522K -0.01%
Aug 3, 2023 74.43 73.16
76.96
73.14
750K -0.39%
Aug 2, 2023 74.72 75.76
76.37
74.37
669K -2.58%
Aug 1, 2023 76.7 76.4
77.27
76.08
316K -0.57%
Jul 31, 2023 77.14 76.74
77.94
75.74
422K 1.03%
Jul 28, 2023 76.35 78.34
78.9
76.15
465K -1.86%
Jul 27, 2023 77.8 76.7
78
76.22
426K 2.42%
Jul 26, 2023 75.96 74.63
76.52
74.15
319K 2.28%
Jul 25, 2023 74.27 73.04
75
73.04
1.1M 1.70%
Jul 24, 2023 73.03 74.29
75.26
72.99
655K -2.44%
Jul 21, 2023 74.86 76.71
76.95
74.75
866K -1.64%
Jul 20, 2023 76.11 77.14
77.68
75.88
551K -1.65%
Jul 19, 2023 77.39 79.64
80.28
76.67
326K -1.74%
Jul 18, 2023 78.76 78.7
79.31
77.44
370K 0.66%
Jul 17, 2023 78.24 78.42
78.73
76.79
603K 0%